Stockscreener 앱 받기
4.61
2.12%
-0.10
시간 외 거래:
4.51
-0.10
-2.17%
Precision Biosciences Inc 주식(DTIL)의 최신 뉴스
SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan
Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com Australia
Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India
Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com Canada
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN
Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India
Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer
Precision BioSciences Reports Positive 2024 Financial Results - TipRanks
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq
Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener
Precision BioSciences Inc Q4 Sales Decline - Nasdaq
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire
Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan
Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com Australia
Precision Biosciences CEO sells $5,359 in stock - Investing.com India
Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire
PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq
Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire
Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26 - StockTitan
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $60 target on Precision BioSciences stock - Investing.com
Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus EliminationKey Trial Updates - Stock Titan
Precision Bio rises after gene editing data: BMO upgrades (update) - MSN
Assessing Precision BioSciences: Insights From 4 Financial Analysts - Benzinga
FDA Clears First-Ever In Vivo Gene-Editing Trial for Chronic Hepatitis B in the United States - CRISPR Medicine News
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - 01Net
Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients - StockTitan
Precision BioSciences' IND Application For PBGENE-HBV Gets FDA Clearance; Stock Climbs - RTTNews
Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance - MarketScreener
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - NewsBreak: Local News & Alerts
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - BioSpace
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
10.70%
자본화:
|
볼륨(24시간):